5AHU
T. Brucei Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-1326
Summary for 5AHU
| Entry DOI | 10.2210/pdb5ahu/pdb |
| Descriptor | FARNESYL PYROPHOSPHATE SYNTHASE, PUTATIVE, FARNESYL PYROPHOSPHATE SYNTHASE, [2-(1-heptyl-1H-imidazol-3-ium-3-yl)ethane-1,1-diyl]bis(phosphonate), ... (5 entities in total) |
| Functional Keywords | transferase |
| Biological source | TRYPANOSOMA BRUCEI More |
| Total number of polymer chains | 4 |
| Total formula weight | 82774.47 |
| Authors | Yang, G.,Oldfield, E.,No, J.H. (deposition date: 2015-02-09, release date: 2015-10-28, Last modification date: 2024-01-10) |
| Primary citation | Yang, G.,Zhu, W.,Kim, K.,Byun, S.Y.,Choi, G.,Wang, K.,Cha, J.S.,Cho, H.,Oldfield, E.,No, J.H. Inhibition of Trypanosoma Brucei Cell Growth by Lipophilic Bisphosphonates: An in Vitro and in Vivo Investigation. Antimicrob.Agents Chemother., 59:7530-, 2015 Cited by PubMed Abstract: We report the results of a screen of a library of 925 potential prenyl synthase inhibitors against Trypanosoma brucei farnesyl diphosphate synthase (TbFPPS) and against T. brucei, the causative agent of human African trypanosomiasis. The most potent compounds were lipophilic analogs of the bone resorption drug zoledronate, some of which had submicromolar to low micromolar activity against bloodstream form T. brucei and selectivity indices of up to ∼ 300. We evaluated the effects of two such inhibitors on survival and parasitemia in a T. brucei mouse model of infection and found that survival increased by up to 16 days. We also investigated the binding of three lipophilic bisphosphonates to an expressed TbFPPS using crystallography and investigated the thermodynamics of binding using isothermal titration calorimetry. PubMed: 26392508DOI: 10.1128/AAC.01873-15 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.69 Å) |
Structure validation
Download full validation report
